Alivus Life Sciences Ltd.

NSE: ALIVUS | BSE: 543322

Expensive Performer

Download real time

1033.80 -47.35 (-4.38%)

38.98% Gain from 52W Low

77,976 NSE+BSE Volume

High vol. this week

NSE 01 Apr, 2025 3:31 PM (IST)

12,667.9

Market Cap

High in industry

0.4

Beta 1Year

Very Low volatility

Alivus Life Sciences Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Alivus Life Sciences Ltd. from all sources in a single place.

Load latest

Alivus Life Sciences Ltd.

09 Oct 2024

1033.80

-4.38%

Company Update

Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Change of Company Name

BSE India

Enclosed please find attached intimation under Regulation 30 of SEBI(LODR), Regulations, 2015 - Change of Company Name

Alivus Life Sciences Ltd.

03 Oct 2024

1033.80

-4.38%

Company Update

Glenmark Life Sciences Ltd - 543322 - Disclosure Under Regulation 30 Of The Securities And Exchange …

BSE India

Please refer enclosed file.

Alivus Life Sciences Ltd.

25 Sep 2024

1033.80

-4.38%

AGM

Glenmark Life Sciences Ltd - 543322 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

BSE India

Find attached Scrutinizer report

Alivus Life Sciences Ltd.

25 Sep 2024

1033.80

-4.38%

AGM

Glenmark Life Sciences Ltd - 543322 - Shareholder Meeting / Postal Ballot-Outcome of AGM

BSE India

Please find attached herewith proceedings of 13th Annual General Meeting.

Alivus Life Sciences Ltd.

18 Sep 2024

1033.80

-4.38%

Aurobindo to acquire remaining 49% stake in GLS Pharma for Rs 22.5 crore

Business Standard

Aurobindo Pharma Ltd on Wednesday said it will acquire the balance 49 per cent stake in GLS Pharma Ltd for Rs 22.5 crore to make the latter a wholly-owned subsidiary. The company has entered into a binding agreement on September 18, 2024, with GLS Pharma Ltd and its promoters for acquisition of remaining 5,90,361 equity shares of Rs 10 each amounting to 49 per cent stake for a purchase consideration of Rs 22.5 crore. The shares are being acquired at a price of Rs 381.12 per share, Aurobindo Pharma said in a regulatory filing. "This acquisition is undertaken to hold the entire ownership of GLS by the company," it said, adding that the transaction is estimated to be completed before December 31, 2024. Aurobindo acquired a 51 per cent stake in GLS Pharma from promoters Suresh Pathak and his family members on June 17, 2022. GLS is engaged in oncology products, which include orals and injectables used in chemotherapy for solid malignancies, chemotherapy for hematological malignancies an

Alivus Life Sciences Ltd. has gained 31.69% in the last 1 Year

Alivus Life Sciences Ltd.

16 Sep 2024

1033.80

-4.38%

Company Update

Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …

BSE India

Please find attached herewith intimation regarding Schedule of Analyst/ Investors Meet.

Alivus Life Sciences Ltd.

04 Sep 2024

1033.80

-4.38%

Company Update

Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached herewith Newspaper Advertisement of Notice of 13th Annual Genereal Meeting and E- Voting Information.

Alivus Life Sciences Ltd.

03 Sep 2024

1033.80

-4.38%

Company Update

Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …

BSE India

Please find attached herewith intimation regarding Analyst/ Investor Meet.

Alivus Life Sciences Ltd.

03 Sep 2024

1033.80

-4.38%

Company Update

Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached Newspaper Advertisement for 13th Annual General Meeting.

Alivus Life Sciences Ltd.

02 Sep 2024

1033.80

-4.38%

Corp. Note

Glenmark Life Sciences Ltd - 543322 - Business Responsibility and Sustainability Reporting (BRSR)

BSE India

Please Finad attached herewith Business Responsibility and Sustainability Report of the Company for F.Y. 2023-24.

No results found

VOTE: Is Glenmark Life Sciences Ltd. worth buying?

120 Votes:

Buy 75.0%

Sell 13.33%

Hold 11.67%

RESEARCH REPORTS

Buy SEE REPORTS >

Hold SEE REPORTS >